Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -17.34% is 89% above its 5-year average of -162.42%, near the high end of its 5-year range (-564.55%–-16.48%).
5.43% above its 12-month average of -18.34%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.65%.
RETURN ON ASSETS (ROA)
-17.34%
RETURN ON ASSETS (ROA) AVG TTM
-18.34%
RETURN ON ASSETS (ROA) AVG 3Y
-35.92%
RETURN ON ASSETS (ROA) AVG 5Y
-162.42%
RETURN ON ASSETS (ROA) AVG 10Y
-812.10%
RETURN ON ASSETS (ROA) AVG 15Y
-343.60%
RETURN ON ASSETS (ROA) AVG 20Y
-254.99%
CURRENT VS TTM AVG
+5.43%
CURRENT VS 3Y AVG
+51.72%
CURRENT VS 5Y AVG
+89.32%
CURRENT VS 10Y AVG
+97.86%
CURRENT VS 15Y AVG
+94.95%
CURRENT VS 20Y AVG
+93.20%
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+46.26%
vs the sector median at left
Sunshine Biopharma, Inc.
Market Cap
$946332.00
Return on Assets (ROA)
-17.34%
TTM Avg
-18.34%
3Y Avg
-35.92%
5Y Avg
-162.42%
Market Cap
$901902.00
Return on Assets (ROA)
-1066.69%
TTM Avg
-314.14%
3Y Avg
-238.72%
5Y Avg
-174.21%
Market Cap
$1.01M
Return on Assets (ROA)
-81.60%
TTM Avg
-1375.39%
3Y Avg
-681.84%
5Y Avg
-547.21%
Market Cap
$868077.00
Return on Assets (ROA)
-65.16%
TTM Avg
-80.06%
3Y Avg
-104.26%
5Y Avg
-73.53%
Market Cap
$838843.00
Return on Assets (ROA)
-63.04%
TTM Avg
-106.06%
3Y Avg
-121.33%
5Y Avg
-96.21%
Market Cap
$835994.00
Return on Assets (ROA)
N/A
TTM Avg
7.00%
3Y Avg
-3.42%
5Y Avg
-4.05%
Market Cap
$824550.00
Return on Assets (ROA)
-160.53%
TTM Avg
-148.83%
3Y Avg
-175.96%
5Y Avg
-127.43%
Market Cap
$1.08M
Return on Assets (ROA)
-44.32%
TTM Avg
-57.72%
3Y Avg
-286.30%
5Y Avg
-215.47%
Market Cap
$1.12M
Return on Assets (ROA)
-147.60%
TTM Avg
-223.87%
3Y Avg
-1843.76%
5Y Avg
-4349.14%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sunshine Biopharma, Inc. (SBFM) | $946332.00 | -17.34% | -18.34% | -35.92% | -162.42% |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | -1066.69% | -314.14% | -238.72% | -174.21% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | -81.60% | -1375.39% | -681.84% | -547.21% |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | -65.16% | -80.06% | -104.26% | -73.53% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838843.00 | -63.04% | -106.06% | -121.33% | -96.21% |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | N/A | 7.00% | -3.42% | -4.05% |
| Decoy Therapeutics Inc. (DCOY)vs › | $824550.00 | -160.53% | -148.83% | -175.96% | -127.43% |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | -44.32% | -57.72% | -286.30% | -215.47% |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | -147.60% | -223.87% | -1843.76% | -4349.14% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.13M | -8.84% | -4.56% | 8.88% | 8.88% |
ROA
-17.3%
ROE
-21.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -19.87% |
| 2024-12-31 | -16.80% |
| 2023-12-31 | -16.48% |
| 2022-12-31 | -90.52% |
| 2021-12-31 | -564.55% |
| 2020-12-31 | -266.30% |
| 2019-12-31 | -1691.72% |
| 2018-12-31 | -188.05% |
| 2017-12-31 | -404.00% |
| 2016-12-31 | -5429.30% |
| 2015-12-31 | -245.51% |
| 2014-12-31 | -1348.46% |
| 2013-12-31 | -7973.75% |
| 2012-12-31 | -525.21% |
| 2011-12-31 | -522.37% |
| 2010-12-31 | -258.64% |
| 2009-12-31 | 0.00% |
| 2008-07-31 | -618.51% |
| 2007-07-31 | -88.10% |
